SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors ...

近年来，钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂作为新型降糖药，被发现具有独立于降糖作用的心肾保护效应，逐渐成为CKD合并2型糖尿病（T2D ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

Discover preclinical studies that indicate that empagliflozin reduces liver fat, improves liver function markers, and ...

What is your insight into that? Isaacs: SGLT2 inhibitors such as empagliflozin and dapagliflozin are beneficial in reducing liver fat, and we even have some noninvasive data showing that they ...

SGLT2 inhibitors are a new family of agents ... It is characterized by a complex and highly integrated interaction among pancreas, liver, muscle, adipocytes and neuroendocrine system.

SGLT2 inhibitors were associated with greater reduction in MACE risk among older adults than younger adults with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT2) inhibitors offer a greater ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

It blocks the function of two proteins, known as SGLT1 and SGLT2, which move glucose and sodium across cell membranes and help control blood sugar levels. Other SGLT2 inhibitors do not as ...